ON012380
ON012380 is a kinase inhibitor with an IC50 of 9 nM against BCR-ABL. As a substrate-competitive BCR-ABL inhibitor, ON012380 binds to a non-ATP site, and inhibits the kinase activities of PDGFR, Fyn and LynB at higher concentrations. ON012380 induces apoptosis, inhibits STAT-5 phosphorylation, reduces cell viability and suppresses cell growth in leukemia cells. ON012380 can be used in the research of chronic myeloid leukemia and Imatinib (HY-15463)-resistant chronic myeloid leukemia.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 592543-24-3
- Fòrmula: C22H27NO8S
- Peso molecular:465.52
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Actividad biológica
Descripciòn
|
Bcr-Abl 9 nM (IC50) |
PDGFR |
Fyn |
LynB |
STAT5 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| DU-145 | IC50 |
0.025 μM
Compound: 27d
|
Cytotoxicity against human DU145 cells after 96 hrs by trypan blue exclusion assay
Cytotoxicity against human DU145 cells after 96 hrs by trypan blue exclusion assay
|
[PMID: 21812421] |
| K562 | IC50 |
0.015 μM
Compound: 27d
|
Cytotoxicity against human K562 cells after 96 hrs by trypan blue exclusion assay
Cytotoxicity against human K562 cells after 96 hrs by trypan blue exclusion assay
|
[PMID: 21812421] |
In Vitro
ON012380 (1 nM-1 μM; 30 min pre-incubation, 20 min kinase reaction) potently inhibits wild-type BCR-ABL kinase activity with an IC50 of 9.0 nM, and acts synergistically with Imatinib (HY-15463) to reduce the IC50 to 0.83 nM[1].
ON012380 (0.1 nM-1000 nM; 30 min pre-incubation, 20 min kinase reaction) acts as a substrate-competitive inhibitor of wild-type BCR-ABL, with IC50 values unaffected by ATP concentration but increased by higher Crk substrate concentrations[1].
ON012380 (30 min pre-incubation, 20 min kinase reaction) potently inhibits the kinase activity of the Imatinib-resistant BCR-ABLT315I mutant with an IC50 of 1.5 nM[1].
ON012380 (72 h) reduces viability of K562 and 32Dcl3-p210BCR-ABL cells with an LD50 of 10-15 nM[1].
ON012380 (10 nM-1000 nM; 24 h) dose-dependently inhibits BCR-ABL kinase activity and suppresses STAT-5 phosphorylation in K562 cells[1].
ON012380 (72 h) reduces viability of all tested Imatinib-resistant BCR-ABL mutant-expressing 32Dcl3 cell lines with LD50 values ranging from 5.9 nM to 10.0 nM[1].
ON012380 (1 nM-1000 nM; 24 h) dose-dependently inhibits BCR-ABLT315I kinase activity and suppresses STAT-5 phosphorylation in 32Dcl3-BCR-ABLT315I cells[1].
ON012380 potently inhibits growth of cells expressing wild-type Bcr-Abl and all tested Imatinib-resistant Bcr-Abl mutants (including BCR-ABLT315I) at concentrations < 10 nM, and also inhibits PDGFR- and Lyn-dependent cell proliferation with an IC50 of approximately 80 nM[2].
ON012380 (1.38-9 nM) potently inhibits wild-type Bcr-Abl kinase activity with an IC50 of 9 nM and the Imatinib-resistant Bcr-AblT315I mutant with an IC50 of 1.38 nM via non-ATP competitive binding[3].
ON012380 (<10 nM) induces apoptosis and cell death in Ph+ CML cells expressing the Imatinib-resistant BCR-ABLT315I isoform[3].
ON012380 (2-24 h) reduces viability and induces apoptosis in IL-3-dependent BaF3 cells, wild-type BCR-ABL-transformed BaF3 cells, and BCR-ABLT315I-mutant BCR-ABL-transformed BaF3 cells, with no significant inhibition of BCR-ABL signaling (Stat5 and CrkL phosphorylation)[4].
ON012380 reduces viability with an IC50 of ~300 nM and induces apoptosis in K562, BV-173, and T315I-mutant BCR-ABL-expressing BV-173R CML cells, but has limited activity in Lyn-overexpressing K562R cells, with no associated inhibition of BCR-ABL or Lyn kinase signaling[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:K562 cells
-
Concentration:10 nM; 100nM; 1000nM
-
Incubation Time:24 h
-
Result:Inhibited BCR-ABL kinase activity in a dose-dependent manner.
Inhibited STAT-5 phosphorylation.
-
Cell Line:32Dcl3-BCR-ABLT315I cells
-
Concentration:1 nM; 10 nM; 100nM; 1000nM
-
Incubation Time:24 h
-
Result:Inhibited BCR-ABLT315I kinase activity in a dose-dependent manner.
Inhibited STAT-5 phosphorylation.
In Vivo
ON012380 (100 mg/kg; i.p.; daily; 21 days) produces significant growth inhibition of Bcr-AblT315I-positive leukemias in nude mice without causing hematoxicity[3].
ON012380 (200 mg/kg; i.v.; single dose) does not impair normal hematopoietic colony formation in CD-1 mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:athymic nude mice (female, ncr-ncr, injected i.v. with 1×106 32Dcl3 cells expressing Imatinib-resistant BCR-ABL T315I mutant)[1]
-
Dosage:100 mg/kg (efficacy); 200 mg/kg (7-day safety); 300 mg/kg (single-dose safety)
-
Administration:i.p.; daily; up to 21 days (100 mg/kg, 200 mg/kg); i.v.; single dose (300 mg/kg)
-
Result:Reduced the average number of T315I leukemic cells per 10 blood fields on days 7 and 14 compared to vehicle- and Imatinib-treated groups.
Showed no signs of toxicity, including no body weight loss, ruffled coats, lethargy, or abnormal feces.
Was well tolerated at 100 mg/kg daily i.p. for up to 21 days.
Produced no toxicity at a single 300 mg/kg dose.
Was well tolerated at 200 mg/kg daily dosing for 7 days.
-
Animal Model:CD-1 mice[1]
-
Dosage:200 mg/kg
-
Administration:i.v.; single dose
-
Result:Showed no reduction in colony formation for erythroid (BFU-E), granulocyte (CFU-G), macrophage (CFU-M), granulocyte-macrophage (CFU-GM), or pre-B lymphocyte lineages compared to control mice.
-
Animal Model:Nude mice[3]
-
Dosage:100 mg/kg
-
Administration:i.p.; daily; 21 days
-
Result:Induced significant growth inhibition of T315I leukemias.
Caused no hematoxicity during daily dosing over 3 weeks at doses >100 mg/kg.
Chemical Information
-
No. CAS 592543-24-3
-
Peso molecular 465.52
-
Fòrmula C22H27NO8S
-
SMILES
C(=C/S(CC1=CC(N[C@H](C(O)=O)C)=C(OC)C=C1)(=O)=O)\C2=C(OC)C=C(OC)C=C2OC
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocolo
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)